Ad­comm votes yes on Leqem­bi full OK; Mer­ck brings first IRA law­suit; Spe­cial: LGBTQ+ lead­ers; Best-pay­ing bio­phar­ma jobs; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

Amid this busy week with AS­CO and BIO, you may have no­ticed a change in how our pay­wall op­er­ates. The gist of it: From now on, non-pay­ing ba­sic sub­scribers will get a lim­it­ed amount of free ar­ti­cles each month, af­ter which we’ll ask you to be­come a pre­mi­um sub­scriber to ac­cess our sto­ries. For pre­mi­um sub­scribers, noth­ing will change. Your sup­port has been cru­cial in grow­ing our news­room and we look for­ward to bring­ing more time­ly, unique and in-depth cov­er­age.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.